Moneycontrol PRO

Buy Gland Pharma; target of Rs 3700: Motilal Oswal

Motilal Oswal is bullish on Gland Pharma recommended buy rating on the stock with a target price of Rs 3700 in its research report dated May 20, 2022.

May 21, 2022 / 07:52 PM IST

Motilal Oswal's research report on Gland Pharma

GLAND delivered an in line 4QFY22. India/Rest of the World (RoW) markets led revenue growth in 4QFY22. It remains on track to develop a complex product pipeline and build manufacturing infrastructure to support commercialization. We reduce our FY23/FY24 EPS estimate by 6% each to factor in: a) extended impact of a syringe shortage; b) increased operational cost on account of higher power charges, freight cost, and packaging cost; c) COVID-led delays in approvals for the China market, offset to some extent due to increased captive sourcing of APIs.


We value GLAND at 33x 12-months forward earnings to arrive at our TP of INR3,700. We remain positive on GLAND, given: a) the considerable scope to increase market share in existing products; b) its enhanced capabilities in peptides, hormones, long acting injectables, delivery systems, Biologics; c) its consistent and successful compliance track record; and d) inorganic growth opportunities. We maintain our Buy rating.


For all recommendations report, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on are their own, and not that of the website or its management. advises users to check with certified experts before taking any investment decisions.

Broker Research
first published: May 21, 2022 07:52 pm
ISO 27001 - BSI Assurance Mark